According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:
1. Sotera Health Co (NASDAQ:SHC)
The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: B, Sentiment: A, Safety: B, Financials: C, and AI: C.
Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 24, which is -2 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates SHC as a "A".
SHC passed 8 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock return 34.67% over the past year, overperforming other diagnostic & research stocks by 14 percentage points.
Sotera Health Co has an average 1 year
price target of $18.00, an upside of 3.21% from Sotera Health Co's current stock price of $17.44.
Sotera Health Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Sotera Health Co, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Idexx Laboratories (NASDAQ:IDXX)
The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: B, Sentiment: B, Safety: C, Financials: A, and AI: C.
Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 50, which is 24 points higher than the diagnostic & research industry average of 26.
IDXX passed 17 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 81.15% over the past year, overperforming other diagnostic & research stocks by 60 percentage points.
Idexx Laboratories has an average 1 year
price target of $737.14, a downside of -2.49% from Idexx Laboratories's current stock price of $755.96.
Idexx Laboratories stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Idexx Laboratories, 57.14% have issued a Strong Buy rating, 14.29% have issued a Buy, 28.57% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Danaher (NYSE:DHR)
Danaher (NYSE:DHR) is the #3 top diagnostic & research stock out of 57 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year.
Learn more.
The Component Grade breakdown for Danaher (NYSE:DHR) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: C.
Danaher (NYSE:DHR) has a Due Diligence Score of 29, which is 3 points higher than the diagnostic & research industry average of 26.
DHR passed 10 out of 38 due diligence checks and has average fundamentals. Danaher has seen its stock lose -3.43% over the past year, underperforming other diagnostic & research stocks by -24 percentage points.
Danaher has an average 1 year
price target of $240.40, an upside of 5.23% from Danaher's current stock price of $228.46.
Danaher stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Danaher, 50% have issued a Strong Buy rating, 30% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
